Close Menu

NEW YORK – PerkinElmer has started targeting laboratories in different geographies with its Vanadis system for noninvasive prenatal cell-free DNA testing, following the publication of a European clinical validation study this summer. Earlier this month, the company also started accepting clinical samples at its laboratory in the US and an affiliate laboratory in Malaysia, allowing potential customers to familiarize themselves with the technology prior to making a purchase decision. In parallel, the company continues to collaborate with a US hospital on another clinical validation study.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.